JHVEPhoto/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday.
Omvoh is now indicated for both forms of inflammatory bowel disease, including ulcerative colitis.
Health Canada has also approved a new citrate-free formulation of Omvoh for subcutaneous injection, which contains the same active ingredients as the original Omvoh.
In VIVID-1, Omvoh showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints, the company said.
More on Eli Lilly
- Eli Lilly Comes Out As ADA Winner
- Eli Lilly: I’ve Learned Not To Fight Against The Market (Downgrade)
- Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
- Short bets against S&P 500 healthcare stocks climb in June; MRNA tops list again
- Eli Lilly granted FDA label update for Alzheimer’s drug Kisunla